PRED | AZA | MMF | p-value | |
Baseline FVC % predicted | ||||
University of Chicago (n=93) | 61.4±19.3 | 56.7±14.6 | 60.2±16.3 | 0.627 |
National Jewish Health (n=99) | 64.6±19.1 | 66.4±21.0 | 69.1±19.3 | 0.730 |
University of Kansas Medical Center (n=60) | 68.8±13.5 | 57.0±14.5 | 65.4±20.5 | 0.093 |
Columbia University Medical Center (n=15) | 75.0±14.0 | 60.0±14.0 | 0.063 | |
University of California Davis (n=10) | 65.0±8.0 | 34.0±0.0 | 65.0±21.0 | 0.278 |
Mean FVC change after 52 weeks | ||||
University of Chicago (n=34) | −1.2±14.9% | −7.6±14.8% | −2.3±10.9% | 0.545 |
University of Kansas Medical Center (n=60) | 0.7±15.5% | 5.7±11.1% | 8.8±14.6% | 0.434 |
Columbia University Medical Center (n=15) | −3.2±12.7% | −3.3±14.1% | 0.990 |
Data are presented as mean±sd unless otherwise stated. Due to variation in data availability across multiple tertiary centres, only patients with FVC data available at baseline and at the 52-week time-point were included in this analysis; 52 week follow-up FVC data were not available for the National Jewish Health and University of California Davis cohorts. National Jewish Health: prednisone (PRED), n=73; azathioprine (AZA), n=19; mycophenolate mofetil (MMF), n=7. University of Kansas Medical Center: PRED, n=30; AZA, n=13; MMF, n=17. Columbia University Medical Center: PRED, n=6; AZA, n=0; MMF, n=9. University of California Davis: PRED, n=4; AZA, n=1; MMF, n=5.